Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents (Q40718402)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 March 2010

edit

Language	Label	Description	Also known as
English	Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents	scientific article published on 23 March 2010

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

title

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

main subject

type 2 diabetes

0 references

liraglutide

1 reference

based on heuristic

inferred from title

author

Julio Rosenstock

series ordinal

8

object named as

Julio Rosenstock

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

Eduard Montanya

object named as

Eduard Montanya

series ordinal

4

0 references

Giorgio Sesti

object named as

Giorgio Sesti

series ordinal

2

0 references

John Buse

object named as

John B Buse

series ordinal

1

0 references

author name string

Wolfgang E Schmidt

series ordinal

3

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

Cheng-Tao Chang

series ordinal

5

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

Yizhen Xu

series ordinal

6

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

Lawrence Blonde

series ordinal

7

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

Liraglutide Effect Action in Diabetes-6 Study Group

series ordinal

9

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

language of work or name

English

0 references

publication date

23 March 2010

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

published in

Diabetes Care

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

volume

33

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

issue

6

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

page(s)

1300-1303

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

start time

28 August 2021

1 reference

stated in

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

25 September 2017

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

25 September 2017

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

25 September 2017

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

25 September 2017

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

25 September 2017

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

25 September 2017

Can newer therapies delay the progression of type 2 diabetes mellitus?

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

25 September 2017

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

19 August 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

19 August 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

19 August 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

retrieved

19 August 2018

Identifiers

DOI

10.2337/DC09-2260

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

PMC publication ID

2875443

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

PubMed publication ID

20332351

1 reference

stated in

Europe PubMed Central

PMC publication ID

2875443

retrieved

23 September 2017

ResearchGate publication ID

42440753

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40718402&oldid=1905129220"